Epidemiology

Clinical Tuberculosis, Fifth Edition

Volumn , Issue , 2014, Pages 19-36

  Cohen, Ted ^a   Dye, Christopher ^b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84961217590     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b16604     Document Type: Chapter

References (200)

1. Streiner DL, Norman GR, and Blum HM. PDQ epidemiology. Toronto: BC Decker Inc, 1989.
2. Keeling MJ and Rohani P. Modeling infectious diseases in humans and animals. Princeton: Princeton University Press, 2007.
3. Raviglione MC and Uplekar MW. WHO’s new stop TB strategy. Lancet 2006;367:952-5.
4. Anderson RM and May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press, 1991.
5. WHO (World Health Organization). Global tuberculosis con-trol: WHO report 2011. Geneva: WHO, 2011.
6. United Nations Statistical Division. Millennium development goals. 2012 [October 2012]; Available from: http://millenniu-mindicators.un.org/unsd/mi/mi_goals.asp.
7. Lopez A, et al. (eds.). Global burden of disease and risk fac-tors. New York: The World Bank, 2006.
8. Dye C, et al. Global burden of tuberculosis. Estimated incidence, prevalence, and mortality by country. JAMA 1999;282(7):677-86.
9. Dye C, et al. Measuring tuberculosis burden, trends and the impact of control programmes. Lancet Infect Dis 2008;8:233-43.
10. Styblo K. Epidemiology of tuberculosis, 2nd edn. The Hague: KNCV Tuberculosis Foundation, 1991, 136.
11. Bourdin Trunz B, Fine P, and Dye C. Effect of BCG vac-cination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006;367:1173-80.
12. van Leth F, Van der Werf MJ, and Borgdorff MW. Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule. Bull World Health Organ 2008;86:20-6.
13. Sutherland I, Svandova E, and Radhakrishna S. The develop-ment of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tubercu-losis in the Netherlands. Tubercle 1982;63:255-68.
14. Vynnycky E and Fine PEM. The natural history of tuberculo-sis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 1997;119:183-201.
15. Dye C, et al. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 1998;352:1886-91.
16. Sutherland I. The ten-year incidence of clinical tuberculosis following “conversion” in 2,550 individuals aged 14 to 19 years. Tuberculosis Surveillance and Research Unit Progress Report. The Hague: KNCV, 1968.
17. Borgdorff MW, et al. The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach. Int J Epidemiol 2011;40:964-70.
18. Andrews JR, et al. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis 2012;54:784-91.
19. de Viedma DG, et al. Reinfection plays a role in a population whose clinical/epidemiological characteristics do not favor reinfection. Arch Intern Med 2002;162:1873-79.
20. Richardson M, et al. Multiple Mycobacterium tuberculosis strains in early cultures from patients in a high-incidence community setting. J Clin Microbiol 2002;40:2750-54.
21. Mathema B, et al. Molecular epidemiology of tuberculosis: current insights. Clin Microbiol Rev 2006;19:658-85.
22. Chiang CY and Riley LW. Exogenous reinfection in tubercu-losis. Lancet Infect Dis 2005;5:629-36.
23. Tiemersma EW, et al. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV nega-tive patients: a systematic review. PLoS One 2011;6:e17601.
24. Krebs W. Die Fälle von Lungentuberkulose in der aar-gauischen Heilstätte Barmelweid aus den Jahren 1912-1927. Beiträge zur Klinik der Tuberkulose 1930;74:345-79.
25. Rieder HL. Epidemiologic basis of tuberculosis control, 1st edn. Paris: International Union Against Tuberculosis and Lung Disease, 1999, 1-162.
26. Grigg ERN. The arcana of tuberculosis with a brief epide-miologic history of the disease in the U.S.A. Am Rev Tuberc 1958;78:151-72.
27. Blower SM, et al. The intrinsic transmission dynamics of tuberculosis epidemics. Nat Med 1995;1:815-21.
28. Murray CJL and Salomon JA. Modeling the impact of global tuberculosis control strategies. Proc Natl Acad Sci U S A 1998;95:13881-6.
29. Dye C and Williams BG. Criteria for the control of drug-resistant tuberculosis. Proc Natl Acad Sci U S A 2000;97:8180-5.
30. Vynnycky E and Fine PEM. The long-term dynamics of tuber-culosis and other diseases with long serial intervals: implica-tions of and for changing reproduction numbers. Epidemiol Infect 1998;121:309-24.
31. Dye C and Espinal MA. Will tuberculosis become resistant to all antibiotics? Proc Biol Sci 2001;268:45-52.
32. Shafer RW and Edlin BR. Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade. Clin Infect Dis 1996;22:683-704.
33. Freedberg KA, et al. The cost effectiveness of combina-tion antiretroviral therapy for HIV disease. N Engl J Med 2001;344:824-31.
34. Badri M, Wilson D, and Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002;359:2059-64.
35. Antonucci G, et al. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995;274:143-8.
36. Selwyn PA, et al. A prospective study of the risk of tubercu-losis among intravenous drug users with human immunodefi-ciency virus infection. N Engl J Med 1989;320:545-50.
37. Williams BG and Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003;301:1535-7.
38. Yazdanpanah Y, et al. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol 2001;30:864-71.
39. Stevenson CR, et al. Diabetes and the risk of tuberculosis: a neglected threat to public health? Chronic Illn, in press. 2007;3:228-45.
40. Jeon CY and Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008;5:e152.
41. Corbett EL, et al. Risk factors for pulmonary mycobacterial disease in South African gold miners. A case-control study. Am J Respir Crit Care Med 1999;159:94-9.
42. van Lettow M, Fawzi WW, and Semba RD. Triple trouble: the role of malnutrition in tuberculosis and human immunodefi-ciency virus co-infection. Nutr Rev 2003;61:81-90.
43. Cegielski JP and McMurray DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. Int J Tuberc Lung Dis 2004;8:286-98.
44. Comstock GW and Palmer CE. Long-term results of BCG vaccination in the southern United States. Am Rev Respir Dis 1966;93:171-83.
45. Edwards LB, et al. Height, weight, tuberculous infection, and tuberculous disease. Arch Environ Health 1971;22:106-12.
46. Lönnroth K, et al. Tuberculosis control and elimina-tion 2010-50: cure, care, and social development. Lancet 2010;375:1814-29.
47. Maguire H, et al. Molecular epidemiology of tuberculosis in London 1995-7 showing low rate of active transmission. Thorax 2002;57:617-22.
48. Cuhadaroglu C, et al. Increased risk of tuberculosis in health care workers: a retrospective survey at a teaching hospital in Istanbul, Turkey. BMC Infect Dis 2002;2:14.
49. Geng E, et al. Changes in the transmission of tuberculo-sis in New York City from 1990 to 1999. N Engl J Med 2002;346:1453-8.
50. Carvalho AC, et al. Transmission of Mycobacterium tubercu-losis to contacts of HIV-infected tuberculosis patients. Am J Respir Crit Care Med 2001;164:2166-71.
51. Besser RE, et al. Risk factors for positive mantoux tubercu-lin skin tests in children in San Diego, California: evidence for boosting and possible foodborne transmission. Pediatrics 2001;108:305-10.
52. van Geuns HA, Meijer J, and Styblo K. Results of contact examination in Rotterdam, 1967-1969. Bull Int. Union Tuberc. 1975;50:107-21.
53. Lin HH, Ezzati M, and Murray M. Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PloS Med 2007;4:173-89.
54. Slama K, et al. Tobacco and tuberculosis: a qualitative sys-tematic review and meta-analysis. Int J Tuberc Lung Dis 2007;10:1049-61.
55. Sonnenberg P, et al. HIV-1 and recurrence, relapse, and rein-fection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001;358:1687-93.
56. Tocque K, et al. A case-control study of lifestyle risk fac-tors associated with tuberculosis in Liverpool, North-West England. Eur Respir J 2001;18:959-64.
57. Perez-Padilla R, et al. Cooking with biomass stoves and tuberculosis: a case control study. Int J Tuberc Lung Dis 2001;5:441-7.
58. Gangaidzo IT, et al. Association of pulmonary tuberculosis with increased dietary iron. J Infect Dis 2001;184:936-9.
59. Wilkinson RJ, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 2000;355:618-21.
60. Nnoaham KE and Clarke A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol 2008;37:113-19.
61. Bellamy R, et al. Variations in the NRAMP1 gene and sus-ceptibility to tuberculosis in West Africans. N Engl J Med 1998;338:640-4.
62. Zachariah R, et al. Moderate to severe malnutrition in patients with tuberculosis is a risk factor associated with early death. Trans R Soc Trop Med Hyg 2002;96:291-4.
63. Toungoussova OS, et al. Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia. Int J Tuberc Lung Dis 2002;6:406-14.
64. Sevim T, et al. Treatment adherence of 717 patients with tuberculosis in a social security system hospital in Istanbul, Turkey. Int J Tuberc Lung Dis 2002;6:25-31.
65. Abos-Hernandez R and Olle-Goig JE. Patients hospitalised in Bolivia with pulmonary tuberculosis: risk factors for dying. Int J Tuberc Lung Dis 2002;6:470-4.
66. Pablos-Mendez A, et al. Nonadherence in tuberculosis treat-ment: predictors and consequences in New York City. Am. J Med. 1997;102:164-70.
67. Baker MA, et al. The impact of diabetes on tuberculosis treat-ment outcomes: a systematic review. BMC Med 2011;9:81.
68. Takiff HE. Host genetics and susceptibility. In: Palomino JC, Leao SC, and Ritacco V (eds.). Tuberculosis 2007: from basic science to patient care. Sao Paolo: Amedeo Challenge, 2007.
69. Grange JM, et al. Historical declines in tuberculosis: nature, nurture and the biosocial model. Int J Tuberc Lung Dis 2001;5:208-12.
70. Goldfeld AE, et al. Association of an HLA-DQ allele with clinical tuberculosis. JAMA 1998;279:226-8.
71. Hill AV. Aspects of genetic susceptibility to human infectious diseases. Annu Rev Genet 2006;40:469-86.
72. Fernando SL and Britton WJ. Genetic susceptibility to mycobacterial disease in humans. Immunol Cell Biol 2006;84:125-37.
73. Liu PT, et al. Toll-like receptor triggering of a vita-min D-mediated human antimicrobial response. Science 2006;311:1770-3.
74. Gao L, et al. Vitamin D receptor genetic polymorphisms and tuberculosis: updated systematic review and meta-analysis. Int J Tuberc Lung Dis 2010;14:15-23.
75. Greenwood CM, Fujiwara TM, and Boothroyd LJ. Linkage of tuberculosis to chromosome 2q35 loci, including NRAMP1, in a large aboriginal Canadian family. Am J Hum Genet 2000;67:405-16.
76. Alm JS, et al. Atopy in children in relation to BCG vacci-nation and genetic polymorphisms at SLC11A1 (formerly NRAMP1) and D2S1471. Genes Immun 2002;3:71-7.
77. Schurr E. Is susceptibility to tuberculosis acquired or inher-ited? J Intern Med 2007;261:106-11.
78. Lewis SJ, Baker I, and Davey Smith G. Meta-analysis of vita-min D receptor polymorphisms and pulmonary tuberculosis risk. Int J Tuberc Lung Dis 2005;9:1174-7.
79. Davies RPO, et al. Historical declines in tuberculosis in England and Wales: improving social conditions or natural selection? Int J Tuberc Lung Dis 1999;3:1051-4.
80. McFarlane N. Hospitals, housing and tuberculosis in Glasgow. Soc Hist Med 1989;2:59-85.
81. Vynnycky E and Fine PEM. Interpreting the decline in tuber-culosis: the role of secular trends in effective contact. Int J Epidemiol 1999;28:327-34.
82. McKeown T and Record RG. Reasons for the decline in mor-tality in England and Wales in the nineteenth century. Popul Stud 1962;16:94-122.
83. Lowell AM, Edwards LB, and Palmer CE. Tuberculosis. Vital and health statistics monographs, American public health association. Cambridge: Harvard University Press, 1969.
84. Lipsitch M and Sousa AO. Historical intensity of natu-ral selection for resistance to tuberculosis. Genetics 2002;161:1599-607.
85. Kato-Maeda M, et al. Comparing genomes within the species Mycobacterium tuberculosis. Genome Res 2001;11:547-54.
86. Mostowy S, et al. Genomic deletions suggest a phylogeny for the Mycobacterium tuberculosis complex. J Infect Dis 2002;186:74-80.
87. Newton SM, et al. A deletion defining a common Asian lin-eage of Mycobacterium tuberculosis associates with immune subversion. Proc Natl Acad Sci U S A 2006;103:15594-8.
88. Lopez B, et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuber-culosis genotypes. Clin Exp Immunol 2003;133:30-7.
89. Corbett EL, et al. HIV-1/AIDS and the control of other infec-tious diseases in Africa. Lancet 2002;359:2177-87.
90. Corbett EL, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003;163:1009-21.
91. Corbett EL, et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold min-ers. Am J Respir Crit Care Med 2004;170:673-9.
92. Wood, R., et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis con-trol. Am J Respir Crit Care Med 2007;175:87-93.
93. Williams BG, et al. Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci U S A 2010;107:19485-9.
94. Suthar AB, et al. Antiretroviral therapy for preven-tion of HIV-associated tuberculosis in developing coun-tries: a systematic review and meta-analysis. PLoS Med 2012;9:e1001270.
95. Akolo C, et al. Treatment of latent tuberculosis infec-tion in HIV infected persons. Cochrane Database Syst Rev 2010;1:CD000171.
96. Shilova MV and Dye C. The resurgence of tuberculosis in Russia. Philos Trans R Soc Lond B Biol Sci 2001;356:1069-75.
97. Toungoussova OS, Bjune G, and Caugant DA. Epidemic of tuberculosis in the former Soviet Union: social and biological reasons. Tuberculosis (Edinb) 2006;86:1-10.
98. Atun RA, et al. Barriers to sustainable tuberculosis control in the Russian Federation health system. Bull World Health Organ 2005;83:217-23.
99. Stone R. Social science. Stress: the invisible hand in Eastern Europe’s death rates. Science 2000;288:1732-3.
100. Leon DA, et al. Hazardous alcohol drinking and premature mortality in Russia: a population based case-control study. Lancet 2007;369:2001-9.
101. Borgdorff MW, et al. Analysis of tuberculosis transmis-sion between nationalities in the Netherlands in the period 1993-1995 using DNA fingerprinting. Am J Epidemiol 1998;147:187-95.
102. Murray MB. Molecular epidemiology and the dynamics of tuberculosis transmission among foreign-born people. CMAJ 2002;167:355-6.
103. Lillebaek T, et al. Persistent high incidence of tuberculosis in immigrants in a low-incidence country. Emerg Infect Dis 2002;8:679-84.
104. Verver S, et al. Tuberculosis infection in children who are contacts of immigrant tuberculosis patients. Eur Respir J 2005;26:126-32.
105. Borgdorff MW, et al. Transmission of Mycobacterium tuber-culosis depending on the age and sex of source cases. Am J Epidemiol 2001;154:934-43.
106. Pareek M, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis 2011;11:435-44.
107. Vynnycky E, et al. Limited impact of tuberculosis control in Hong Kong: attributable to high risks of reactivation disease. Epidemiol Infect 2008;136:943-52.
108. Wu P. et al. The transmission dynamics of tuberculosis in a recently developed Chinese city. PLoS One 2010;5:e10468.
109. Sreevatsan S, et al. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evo-lutionarily recent global dissemination. Proc Natl Acad Sci U S A 1997;94:9869-74.
110. Musser JM, Amin A, and Ramaswamy S. Negligible genetic diversity of Mycobacterium tuberculosis host immune sys-tem protein targets: evidence of limited selective pressure. Genetics 2000;155:7-16.
111. Fleischmann RD, et al. Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol 2002;184:5479-90.
112. Gutacker MM, et al. Single-nucleotide polymorphism-based population genetic analysis of Mycobacterium tuberculosis strains from 4 geographic sites. J Infect Dis 2006;193:121-8.
113. Filliol I, et al. Global phylogeny of Mycobacterium tuberculo-sis based on single nucleotide polymorphism (SNP) analysis: insights into tuberculosis evolution, phylogenetic accuracy of other DNA fingerprinting systems, and recommendations for a minimal standard SNP set. J Bacteriol 2006;188:759-72.
114. Hershberg R, et al. High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biol 2008;6:e311.
115. Mathema B, et al. Epidemiologic consequences of microvari-ation in Mycobacterium tuberculosis. J Infect Dis 2012; 205:964-74.
116. Nicol MP and Wilkinson RJ. The clinical consequences of strain diversity in Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg 2008;102:955-65.
117. Barczak AK, et al. In vivo phenotypic dominance in mouse mixed infections with Mycobacterium tuberculosis clinical isolates. J Infect Dis 2005;192:600-6.
118. De Steenwinkel JEM, et al. Drug susceptibility of Mycobacterium tuberculosis Beijing genotype, association with MDR TB. Emerg Infect Dis 2012;18:660-3.
119. Fenner L, et al. Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012;56:3047-53.
120. Basu S, Orenstein E, and Galvani AP. The theoretical influ-ence of immunity between strain groups on the progres-sion of drug-resistant tuberculosis epidemics. J Infect Dis 2008;198:1502-13.
121. Cohen T, Colijn C, and Murray M. Modeling the effects of strain diversity and mechanisms of strain competition on the potential performance of new tuberculosis vaccines. Proc Natl Acad Sci U S A 2008;105:16302-7.
122. Colijn C, Cohen T, and Murray M. Latent coinfection and the maintenance of strain diversity. Bull Math Biol 2009;71:247-63.
123. Shirakawa T, et al. The inverse association between tuberculin responses and atopic disorder. Science 1997;275:77-9.
124. Obihara CC, et al. Inverse association between Mycobacterium tuberculosis infection and atopic rhinitis in children. Allergy 2005;60:1121-5.
125. von Mutius E, et al. International patterns of tuberculosis and the prevalence of symptoms of asthma, rhinitis, and eczema. Thorax 2000;55:449-53.
126. Shirtcliffe P, Weatherall M, and Beasley R. An inverse cor-relation between estimated tuberculosis notification rates and asthma symptoms. Respirology 2002;7:153-5.
127. Baccioglu Kavut A, et al. Association between tuberculosis and atopy: role of the CD14-159C/T polymorphism. J Investig Allergol Clin Immunol 2012;22:201-7.
128. Hopkin JM. Atopy, asthma, and the mycobacteria. Thorax 2000;55:443-5.
129. Obihara CC, et al. Respiratory atopic disease, Ascaris-immunoglobulin E and tuberculin testing in urban South African children. Clin Exp Allergy 2006;36:640-8.
130. Ferreira AP, et al. Can the efficacy of Bacille Calmette-Guerin tuberculosis vaccine be affected by intestinal parasitic infec-tions? J Infect Dis 2002;186:441-2.
131. Group, KPT. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996;348:17-24.
132. Lietman T, Porco T, and Blower S. Leprosy and tuberculosis: the epidemiological consequences of cross-immunity. Am J Public Health 1997;87:1923-7.
133. World Health Organization and Stop TB Partnership. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis. Geneva: WHO, 2010, 1-100.
134. Dye C, et al. Targets for global tuberculosis control. Int J Tuberc Lung Dis 2006;10:460-2.
135. Dowdy DW and Chaisson RE. The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection. Bull World Health Organ 2009;87:296-304.
136. Dye C. Tuberculosis 2000-2010: control, but not elimination. Int J Tuberc Lung Dis 2000;4:S146-52.
137. Centers for Disease Control and Prevention. Tuberculosis (TB). 2012 [cited 25 April 2012]; Available from: http://www.cdc.gov.
138. Health Protection Agency. Tuberculosis (TB). 2012 [cited 25 April 2012]; Available from: http://www.hpa.org.uk.
139. Styblo K, Broekmans JF, and Borgdorff MW. Expected decrease in tuberculosis incidence during the elimination phase. How to determine its trend? Tubercul Surveill Res Unit Prog Rep 1997;1:17-78.
140. Hong YP, et al. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis 1998;2:27-36.
141. China Tuberculosis Control Collaboration. The effect of tuberculosis control in China. Lancet 2004;364:417-22.
142. Wang L, et al. Prevalence and trends in smear-positive and bacteriologically-confirmed pulmonary tuberculosis in China in 2010. Unpublished, 2012.
143. Grzybowski S, Styblo K, and Dorken E. Tuberculosis in Eskimos. Tubercle 1976;57:S1-58.
144. Vree M, et al. Tuberculosis trends, Vietnam. Emerg Infect Dis 2007;13:332-3.
145. Buu TN, et al. Decrease in risk of tuberculosis infection despite increase in tuberculosis among young adults in urban Vietnam. Int J Tuberc Lung Dis 2010;14:289-95.
146. Suarez PG, et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis 2001;184:473-8.
147. Dye C, et al. Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China. Int J Epidemiol 2000;29:558-64.
148. Toman K. Tuberculosis case-finding and chemotherapy. Questions and answers, 1st edn. Geneva: World Health Organization, 1979, 1-239.
149. Marks GB, et al. Effectiveness of postmigration screening in controlling tuberculosis among refugees: a historical cohort study, 1984-1998. Am J Public Health 2001;91:1797-9.
150. Solsona J, et al. Screening for tuberculosis upon admis-sion to shelters and free-meal services. Eur J Epidemiol 2001;17:123-8.
151. Noertjojo K, et al. Contact examination for tuberculosis in Hong Kong is useful. Int J Tuberc Lung Dis 2002;6:19-24.
152. Claessens NJM, et al. High frequency of tuberculosis in households of index TB patients. Int J Tuberc Lung Dis 2002;6:266-9.
153. Nyangulu DS, et al. Tuberculosis in a prison population in Malawi. Lancet 1997;350:1284-7.
154. Golub JE, et al. Active case finding of tuberculosis: histori-cal perspective and future prospects. Int J Tuberc Lung Dis 2005;9:1183-203.
155. Corbett EL, et al. Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive TB and control of infectious TB in Harare, Zimbabwe (DETECTB): a cluster-randomised trial. Lancet 2010;376:1244-53.
156. Kranzer K, et al. A systematic literature review of the benefits to communities and individuals of screening for active tuberculosis disease. Int J Tuberc Lung Dis. 2013;17:432-46.
157. Currie CSM, et al. Tuberculosis epidemics driven by HIV: is prevention better than cure? AIDS 2003;17:2501-8.
158. Dodd PJ, White RG, and Corbett EL. Periodic active case finding: when to look? PLoS One 2012;6:e29130.
159. Churchyard G, et al. Community-wide isoniazid preven-tive therapy does not improve TB control among gold miners: the Thibela TB study, South Africa. In: 19th Conference on Retroviruses and Opportunistic Infections, Seattle, 5-8 March 2012.
160. Cohn DL and El-Sadr WM. Treatment of latent tubercu-losis infection. In: Reichman LB and Hershfield ES (eds.) Tuberculosis: a comprehensive international approach. New York: Marcel Dekker, 2000.
161. Lee LM, et al. Low adherence to guidelines for preventing TB among persons with newly diagnosed HIV infection, United States. Int J Tuberc Lung Dis 2006;10:209-14.
162. WHO (World Health Organization). Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: WHO, 2011.
163. Stop TB Partnership and World Health Organization. The global plan to stop TB, 2006-2015. Geneva: Stop TB Partnership, 2006.
164. Boyles TH and Maartens G. Should tuberculin skin testing be a prerequisite to prolonged IPT for HIV-infected adults? Int J Tuberc Lung Dis 2012;16:857-9.
165. Lawn SD and Wood R. Short-course untargeted isoniazid pre-ventive therapy in South Africa: time to rethink policy? Int J Tuberc Lung Dis 2012;16:995-6.
166. Tulsky JP, et al. Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial. Arch Intern Med 2000;160:697-702.
167. Wilkinson D, Squire SB, and Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: sys-tematic review of randomised placebo controlled trials. BMJ 1998;317:625-9.
168. Bucher HC, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled tri-als. AIDS 1999;13:501-7.
169. Johnson JL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001;15:2137-47.
170. Quigley MA, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001;15:215-22.
171. Whalen CC, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immu-nodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337:801-8.
172. Mwinga A, et al. Twice weekly tuberculosis preventive ther-apy in HIV infection in Zambia. AIDS 1998;12:2447-57.
173. Woldehanna S and Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004;1:CD000171.
174. Samandari T, et al. 6-month versus 36-month isoniazid pre-ventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011;377:1588-98.
175. Samandari T, et al. TB incidence increase after cessation of 36 months’ isoniazid prophylaxis in HIV+ adults: Botswana. In: 19th Conference on Retroviruses and Opportunistic Infections, Seattle, 5-8 March 2012.
176. Zar HJ, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 2007;334:136.
177. Ayles H and Muyoyeta M. Isoniazid to prevent first and recur-rent episodes of TB. Trop Doct 2006;36:83-6.
178. Zignol M, et al. Surveillance of anti-tuberculosis drug resis-tance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012;90:111-19D.
179. Sergeev R, et al. Modeling the dynamic relationship between HIV and the risk of drug-resistant tuberculosis. Sci Transl Med 2012;4:135ra67.
180. WHO (World Health Organization). Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. Geneva: WHO, 2011.
181. Raviglione MC and Smith IM. XDR tuberculosis - implications for global public health. N Engl J Med 2007;356:656-9.
182. Dye C, et al. Erasing the world’s slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002;295: 2042-6.
183. Cohen T, Sommers B, and Murray M. The effect of drug resis-tance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 2003;3:13-21.
184. O’Sullivan DM, McHugh TD, and Gillespie SH. Mapping the fitness of Mycobacterium tuberculosis strains: a complex pic-ture. J Med Microbiol 2010;59:1533-5.
185. Menzies D, et al. Standardized treatment of active tubercu-losis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009;6:e1000150.
186. Dye C and Williams BG. Slow elimination of multidrug-resistant tuberculosis. Sci Transl Med 2009;1:3ra8.
187. Streicher EM, et al. Emergence and treatment of multi-drug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa. Inf Genet Evol 2012;12: 686-94.
188. Ioerger TR, et al. The non-clonality of drug resistance in Beijing-genotype isolates of Mycobacterium tuberculosis from the Western Cape of South Africa. BMC Genomics 2010;11:670.
189. Cohen T and Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 2004;10:1117-21.
190. Blower SM and Chou T. Modeling the emergence of the ‘hot zones’: tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004;10:1111-16.
191. Dye C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat Rev Microbiol 2009;10:81-7.
192. Mitnick C, et al. Community-based therapy for multi-drug-resistant tuberculosis in Lima, Peru. N Engl J Med 2003;348:119-28.
193. Mitnick CS, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008;359:563-74.
194. Van Deun A, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-92.
195. WHO (World Health Organization) (ed.). Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update. Geneva: WHO, 2011.
196. Fine PEM. BCG vaccines and vaccination. In: Reichman LB and Hershfield ES (eds.). Tuberculosis: a comprehensive international approach. New York: Marcel Dekker, 2001.
197. WHO (World Health Organization). WHO vaccine preventable diseases: monitoring system. 2011 global summary. Geneva: Immunization, Vaccines and Biologicals, WHO, 2011.
198. Young DB and Dye C. The development and impact of tuber-culosis vaccines. Cell 2006;124:683-7.
199. Trebucq A, et al. Xpert(R) MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int J Tuberc Lung Dis 2011;15:1567-72.
200. Dye C, et al. Prospects for tuberculosis elimination. Annu Rev Public Health 2013;34:271-86.